Clinical Trials Directory

Trials / Recruiting

RecruitingNCT06457334

Effect of Helicobacter Pylori Eradication on Gastroesophageal RefIux Disease (GERD)

Status
Recruiting
Phase
Study type
Observational
Enrollment
100 (estimated)
Sponsor
Assiut University · Academic / Other
Sex
All
Age
Healthy volunteers
Not accepted

Summary

Evaluate the effect of H.pylori eradication on Gastroesophageal-reflux disease and symptoms improvement

Detailed description

HeIicobacter PyIori (H.pyIori) is a gram-negative spiral shaped bacterium that affects up to 50% of the population worldwide, with a higher prevalences in the developing countries,Gastroesophageal reflux disease (GERD) is a chronic gastrointestinal disorder characterized by the regurgitation of gastric contents into the esophagus, resulting in a significant economic burden in direct and indirect costs and adversely affects the quality of life.GERD is caused by multiple different mechanisms that can be intrinsic, structural, or both, leading to the disruption of the esophago-gastric junction barrier resulting in exposure of the esophagus to acidic gastric contents, Clinically, GERD typically manifests with symptoms of heartburn and regurgitation. It can also present in an atypical fashion with extra-esophageal symptoms such as chest pain, dental erosions, chronic cough, laryngitis, or asthma.The relationship between H. pylori and gastroesophageal reflux disease (GERD) is still unclear, and the effect of H. pylori eradication on GERD treatment is unknown.Several studies have shown the inverse relationship between the occurrence of GERD and H.pyIori infection, in particular an increased severity of the disease is documented in patients with pre-existing symptoms .It has been showed that a markedly resolution of dyspepsia in patients at whom the eradication therapy was successful when compared with subjects with a persistent infection

Conditions

Timeline

Start date
2024-01-01
Primary completion
2024-12-31
Completion
2025-01-01
First posted
2024-06-13
Last updated
2024-06-13

Locations

1 site across 1 country: Egypt

Source: ClinicalTrials.gov record NCT06457334. Inclusion in this directory is not an endorsement.